Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 764,829
  • Shares Outstanding, K 254,096
  • Annual Sales, $ 130 K
  • Annual Income, $ -234,630 K
  • 60-Month Beta -0.56
  • Price/Sales 5,883.30
  • Price/Cash Flow N/A
  • Price/Book 1.16
Trade LYEL with:

Options Overview Details

View History
  • Implied Volatility 163.68% ( -65.23%)
  • Historical Volatility 118.79%
  • IV Percentile 80%
  • IV Rank 31.19%
  • IV High 516.75% on 09/27/23
  • IV Low 3.65% on 05/09/23
  • Put/Call Vol Ratio 0.82
  • Today's Volume 60
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 774
  • Open Int (30-Day) 710

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.21
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +25.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +30.43%
on 03/19/24
3.14 -23.69%
on 04/12/24
+0.24 (+11.11%)
since 03/15/24
3-Month
1.69 +42.01%
on 02/09/24
3.26 -26.28%
on 03/04/24
+0.18 (+8.11%)
since 01/12/24
52-Week
1.32 +81.82%
on 10/09/23
3.97 -39.55%
on 06/16/23
+0.04 (+1.69%)
since 04/14/23

Most Recent Stories

More News
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

/PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy...

LYEL : 2.40 (-20.27%)
Why Shares of Lyell Immunopharma Jumped This Week

The company gave a presentation regarding its lead therapy to treat solid tumors.

GS : 400.88 (+2.92%)
LYEL : 2.40 (-20.27%)
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 2.40 (-20.27%)
CTLT : 56.08 (-0.39%)
Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

AUPH : 5.04 (-1.18%)
LYEL : 2.40 (-20.27%)
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYEL : 2.40 (-20.27%)
LYRA : 5.27 (-0.19%)
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

LYEL : 2.40 (-20.27%)
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 2.40 (-20.27%)
AFIB : 0.1704 (-2.68%)
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?

Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LYEL : 2.40 (-20.27%)
XERS : 1.8500 (-3.14%)
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DRRX : 0.7957 (+3.90%)
LYEL : 2.40 (-20.27%)
Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CTLT : 56.08 (-0.39%)
LYEL : 2.40 (-20.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 3.28
2nd Resistance Point 3.08
1st Resistance Point 2.74
Last Price 2.40
1st Support Level 2.21
2nd Support Level 2.01
3rd Support Level 1.67

See More

52-Week High 3.97
Fibonacci 61.8% 2.96
Fibonacci 50% 2.64
Last Price 2.40
Fibonacci 38.2% 2.33
52-Week Low 1.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar